Despite some market exclusivity concerns, GERN still has many years of sales ahead, unencumbered by generic competition.

Goldman Sachs analyst Matthew Sykes raised the firm’s price target on Cytek Biosciences (CTKB) to $5.25 from $4.50 and keeps a Sell rating on ...

The Boeing Company faces short-term struggles with negative operating cash flow, but it has a strong cash position and ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...

Atlassian reported second-quarter revenue of $1.29 billion, beating analyst estimates of $1.24 billion, according to Benzinga ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

Boeing reported a 31% revenue decline in Q4 2024, with adjusted loss per share of $5.90. Commercial airplane revenue fell 55% ...

Winning means losing. Ohio State captured the CFP title and quickly saw offensive coordinator Chip Kelly and defensive ...

Shares in Check Point Software Technologies Ltd. rose more than 7% in regular trading today after the cybersecurity company ...

CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a ...